Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3884961 in Infants With Type 2 Gaucher Disease
NCT04411654Phase 2Active, not recruiting
- Sponsor
- Prevail Therapeutics Inc.
- Start
- Jun 2021
- Primary completion
- Feb 2027
- Countries
- 2
01
Overview
A Phase 2 trial of LY3884961 in Gaucher disease type 2 (GD2), sponsored by Prevail Therapeutics Inc.. Started Jun 2021; status: active, not recruiting.
02
Drugs
LY3884961
03
Conditions
Gaucher disease type 2 (GD2)
Beyond the preview
Go deeper on NCT04411654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411654.